RESEARCH
O&G Forum 2024; 34-3s: 1075-1079

Cyberknife Boost for Prostatic Carcinoma: Approaches in General Surgery

Deshmukh Shantanu Diwakarrao (Junior Resident)[1], Dr. Nitin Nangare (Professor)[2], Dr. Minal Pahuja (Junior Resident)[3]
Department of General Surgery, Krishna Institute of Medical Sciences, KVV, Karad.
Corresponding author-
Dr. Deshmukh Shantanu Diwakarrao (Junior Resident), Department of General Surgery, Krishna Institute of Medical Sciences, KVV, Karad.

Abstract
Numerous randomized trials have juxtaposed the efficacy of escalated doses of external beam radiation against a regimen involving external radiation followed by a brachytherapy boost in cases of locally advanced prostatic carcinomas. The findings consistently demonstrate the superiority of the latter approach. However, it is imperative to meticulously evaluate the biologically equivalent dose (BED) administered in such protocols, along with discerning the radiobiological disparities between the two modalities. Conventional fractionated external beam radiotherapy facilitates dose escalation but lacks the inherent radiobiological advantages of brachytherapy, which inherently delivers higher doses per fraction. Utilizing CyberKnife with stereotactic body radiation therapy (SBRT) as a boost overcomes this limitation, enabling safe dose escalation through external radiation. The efficacy of radiosurgical ablation in managing low-risk prostatic carcinomas is well-established. In our investigation, within the realm of general surgery, we scrutinized the local control rates and toxicity profiles of 31 patients diagnosed with high-risk prostatic adenocarcinoma. These patients underwent neoadjuvant hormone therapy followed by external beam radiation employing tomotherapy, complemented by a CyberKnife boost.
Keywords:Prostatic adenocarcinoma Intensity-modulated radiation therapy (IMRT) Stereotactic body radiation therapy (SBRT) High-risk prostate cancer Treatment outcomes

INTRODUCTION

In the dynamic landscape of oncology, the pursuit of optimal treatment strategies for prostatic carcinoma remains a focal point of research and clinical endeavors. Among the myriad therapeutic modalities available, the integration of advanced radiation techniques within the purview of general surgery has emerged as a promising avenue in enhancing therapeutic outcomes and mitigating treatment-related toxicities. Prostate cancer represents a significant health burden globally, with its incidence steadily rising in recent years. While localized disease often presents with favorable prognoses, the management of locally advanced and high-risk cases poses formidable challenges. Historically, external beam radiation therapy (EBRT) has served as a cornerstone in the treatment armamentarium, delivering radiation to the prostate gland and surrounding tissues to eradicate malignant cells. However, the quest for improved efficacy and reduced toxicity has spurred the exploration of novel approaches, culminating in the advent of CyberKnife technology and its application in boosting radiation doses for prostatic carcinoma.

The seminal shift in treatment paradigms arose from the juxtaposition of various randomized trials, comparing the outcomes of dose escalated EBRT with those of combined external radiation and brachytherapy boost regimens. These trials, meticulously designed and executed, have furnished compelling evidence in favor of the latter approach, underscoring its superiority in achieving superior disease control and minimizing treatment failure rates. Notably, the biologically equivalent dose (BED) emerged as a critical metric in evaluating the efficacy of these treatment modalities, illuminating the radiobiological nuances that underpin therapeutic success. Central to this discourse is the concept of dose escalation and its implications for optimizing therapeutic outcomes in prostatic carcinoma. Conventionally fractionated EBRT, while capable of delivering escalated doses over prolonged treatment courses, inherently lacks the radiobiological advantages conferred by brachytherapy, where higher doses per fraction can be administered with precision. This fundamental dichotomy underscores the need for innovative solutions that reconcile the efficacy of dose escalation with the radiobiological imperatives of prostate cancer treatment.Enter CyberKnife, a revolutionary technology heralding a new era in radiation oncology. By harnessing the principles of stereotactic body radiation therapy (SBRT), CyberKnife enables the precise delivery of high-dose radiation to target volumes with unparalleled accuracy and conformality. Moreover, its unique ability to track and adjust for intrafractional motion confers a distinct advantage in mitigating the uncertainties associated with prostate motion during treatment delivery. It is within this context that CyberKnife assumes prominence as a viable adjunct in prostate cancer management, offering a potent means of dose escalation while circumventing the radiobiological limitations inherent in conventional EBRT. The role of radiosurgical ablation in low-risk prostatic carcinomas has been well-established, with favorable outcomes reported in numerous studies. However, its utility in high-risk disease remains a subject of ongoing investigation, warranting comprehensive evaluation within the realm of general surgery. Against this backdrop, our study endeavors to elucidate the efficacy and safety profile of CyberKnife boost in conjunction with neoadjuvant hormone therapy and tomotherapy-based EBRT in patients with high-risk prostatic adenocarcinoma. Through a meticulous analysis of clinical data encompassing 31 patients, we aim to delineate the impact of CyberKnife boost on local control rates and treatment-related toxicities in this cohort. By scrutinizing both objective endpoints and patient-reported outcomes, we seek to provide a comprehensive assessment of the therapeutic landscape, shedding light on the feasibility and efficacy of this innovative approach in the management of high-risk prostatic carcinoma.In traversing the intricate terrain of prostate cancer management, our study underscores the pivotal role of CyberKnife technology within the realm of general surgery. By harnessing the synergistic potential of advanced radiation techniques, we endeavor to optimize therapeutic outcomes, minimize treatment-related morbidities, and ultimately, improve the quality of life for patients grappling with this formidable disease. As we embark on this investigative journey, we remain steadfast in our commitment to advancing the frontiers of oncological care and ushering in a new era of precision medicine in the fight against prostatic carcinoma.

Research Gap:

In the vast expanse of prostate cancer research and treatment, a discernible gap exists concerning the optimal integration of CyberKnife technology within the realm of general surgery for high-risk prostatic adenocarcinoma. While the efficacy of CyberKnife as a boost in low-risk disease settings has been extensively studied and validated, its utility in the context of high-risk disease remains relatively underexplored. Existing literature predominantly focuses on conventional treatment modalities and lacks comprehensive investigations into the role of CyberKnife boost in augmenting therapeutic outcomes for high-risk prostatic carcinoma. Moreover, few studies have delved into the radiobiological underpinnings of CyberKnife-mediated dose escalation and its implications for disease control and treatment-related toxicities.

Thus, there exists a compelling need to bridge this gap in knowledge and delineate the potential benefits of CyberKnife boost in conjunction with neoadjuvant hormone therapy and tomotherapy-based external beam radiation therapy (EBRT) within the specific subset of patients with high-risk prostatic adenocarcinoma.

Specific Aims of the Study:

1. **Evaluate the Efficacy of CyberKnife Boost:** The primary aim of this study is to assess the impact of CyberKnife boost on local control rates in patients with high-risk prostatic adenocarcinoma. By analyzing disease recurrence patterns and progression-free survival rates, we aim to elucidate the therapeutic efficacy of CyberKnife in augmenting disease control within this patient population.
2. **Characterize Treatment-related Toxicities:** A secondary aim of this study is to characterize treatment-related toxicities associated with CyberKnife boost in conjunction with neoadjuvant hormone therapy and tomotherapy-based EBRT. By employing standardized toxicity grading systems and patient-reported outcome measures, we seek to delineate the safety profile of this treatment approach and identify potential adverse effects that may influence treatment tolerability and patient quality of life.

Objectives of the Study:

1. To prospectively enroll a cohort of 31 patients diagnosed with high-risk prostatic adenocarcinoma, eligible for neoadjuvant hormone therapy followed by tomotherapy-based EBRT with CyberKnife boost.
2. To administer neoadjuvant hormone therapy according to established protocols, achieving adequate androgen deprivation prior to initiating radiation therapy.
3. To deliver tomotherapy-based EBRT to the prostate gland and pelvic lymph nodes, utilizing conformal treatment planning techniques to optimize target coverage while minimizing doses to surrounding normal tissues.
4. To administer CyberKnife boost to the prostate gland, employing stereotactic body radiation therapy (SBRT) techniques to deliver escalated doses with submillimeter precision and minimal toxicity.
5. To perform regular follow-up assessments at predefined intervals, including clinical evaluations, imaging studies, and laboratory investigations, to monitor treatment response and detect disease recurrence or progression.
6. To analyze clinical data, including disease outcomes, treatment-related toxicities, and patient-reported outcomes, using statistical methods to derive meaningful conclusions regarding the efficacy and safety of CyberKnife boost in high-risk prostatic adenocarcinoma.

Scope of the Study:

This study is designed to comprehensively evaluate the role of CyberKnife boost in the management of high-risk prostatic adenocarcinoma within the framework of general surgery. By focusing on a specific subset of patients with high-risk disease features, we aim to provide valuable insights into the therapeutic potential of CyberKnife technology in augmenting disease control and minimizing treatment-related toxicities. The scope of the study encompasses prospective enrollment, standardized treatment delivery, rigorous follow-up assessments, and comprehensive data analysis, culminating in a nuanced understanding of the clinical utility of CyberKnife boost in this patient population.

Conceptual Framework:

The conceptual framework underlying this study is rooted in the principles of precision medicine and multidisciplinary oncological care. By integrating advanced radiation techniques, such as CyberKnife technology, within the purview of general surgery, we seek to tailor treatment strategies to the unique biological and clinical characteristics of high-risk prostatic adenocarcinoma. This framework encompasses a holistic approach to patient care, emphasizing the optimization of therapeutic outcomes while minimizing treatment-related morbidities. Central to this framework is the concept of dose escalation and its implications for enhancing disease control, guided by a nuanced understanding of radiobiological principles and treatment efficacy.

Hypothesis:

We hypothesize that the incorporation of CyberKnife boost in conjunction with neoadjuvant hormone therapy and tomotherapy-based EBRT will result in improved local control rates and favorable treatment-related toxicity profiles in patients with high-risk prostatic adenocarcinoma. Specifically, we anticipate that CyberKnife-mediated dose escalation will enhance tumor eradication while minimizing doses to adjacent normal tissues, thereby reducing the risk of treatment-related toxicities and improving patient quality of life. Furthermore, we hypothesize that CyberKnife boost will confer radiobiological advantages over conventional EBRT, resulting in superior disease control outcomes and prolonged progression-free survival rates in this patient population. Through rigorous prospective evaluation and comprehensive data analysis, we aim to validate these hypotheses and elucidate the therapeutic potential of CyberKnife technology in high-risk prostatic adenocarcinoma within the realm of general surgery.

Research Methodology:

Study Design: This retrospective study aimed to evaluate the efficacy and safety of CyberKnife boost in conjunction with neoadjuvant hormonal therapy and tomotherapy-based external beam radiation therapy (EBRT) in patients with histologically proven high-risk prostatic adenocarcinoma.

Patient Selection: From our hospital registry, 31 patients meeting specific inclusion criteria were identified for inclusion in the study. Inclusion criteria encompassed histologically confirmed adenocarcinoma, Gleason grade ≥ 7, clinical stage T2b or higher, baseline PSA $\geq$ 20, and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients who met any of the predefined exclusion criteria, including previous pelvic radiotherapy, distant metastatic disease, or multiple primary malignancies, were excluded from the study.

Treatment Protocol: All eligible patients underwent neoadjuvant hormonal therapy for a duration of 3 months prior to initiating radiation therapy. Hormonal therapy was continued for 2 years post-treatment. External beam radiation was delivered using tomotherapy technique to a total dose of 45-50 Gy. Subsequently, patients received 2-3 fractions of CyberKnife boost post fiducial marker placement.

Image-Guided Radiation Therapy (IGRT) Treatment Delivery: Prior to IGRT planning, all patients underwent PSMA PET CT simulation to facilitate accurate treatment planning and delivery.

Stereotactic Body Radiation Therapy (SBRT) Treatment Planning & Delivery: CyberKnife boost was delivered using SBRT techniques, leveraging the precise targeting capabilities of the system. Treatment planning involved meticulous delineation of target volumes and critical structures to optimize dose delivery while minimizing toxicity. Delivery of CyberKnife boost was facilitated post fiducial marker placement to ensure accurate localization of the target.

Follow-up and Toxicity Assessment: Following completion of treatment, patients underwent regular follow-up assessments to monitor treatment response and assess for any potential toxicities. Clinical evaluations, imaging studies, and laboratory investigations were conducted at predefined intervals to track disease progression and treatment-related adverse events. Toxicity assessment was performed using standardized grading systems to characterize the nature and severity of any observed toxicities.

Data Analysis: Clinical data, including treatment outcomes and toxicity profiles, were collected and analyzed using appropriate statistical methods. Descriptive statistics were utilized to summarize patient demographics, disease characteristics, and treatment parameters. Kaplan-Meier analysis was employed to estimate survival outcomes, including local control rates and progression-free survival. Additionally, subgroup analyses were conducted to explore potential correlations between treatment variables and clinical endpoints.

Ethical Considerations: This study was conducted in accordance with the principles outlined in the Declaration of Helsinki and received approval from the institutional review board. Informed consent was obtained from all patients prior to inclusion in the study, and measures were implemented to ensure patient confidentiality and privacy throughout the research process.

Results and Analysis:

Patient Characteristics: A total of 31 prostate cancer patients who underwent intensity-modulated radiation therapy (IMRT) with stereotactic body radiation therapy (SBRT) boost were included in this retrospective study. Descriptive statistics were performed on the collected data to elucidate the demographic and clinical characteristics of the patient cohort. The median follow-up duration was 24.4 months, during which various parameters were assessed to gauge treatment efficacy and toxicity profiles

.



Figure 1: IGRT Treatment Delivery.

The median age of the patients at the time of treatment initiation was 74 years, with a wide age range spanning from 46 to 89 years. Notably, the majority of patients exhibited good baseline health, as evidenced by Eastern Cooperative Oncology Group (ECOG) performance status scores of 0-1. The median pre-treatment prostate-specific antigen (PSA) level was notably elevated, with a median value of 64 ng/ml, indicative of high disease burden at baseline.

Treatment Parameters: The majority of patients (90.4%) received a total radiation dose of 50 Gy administered in 25 fractions, while a smaller subset (9.6%) underwent treatment with a slightly lower dose of 45 Gy in 25 fractions. This variation in treatment dose may reflect individualized treatment decisions based on patient-specific factors and disease characteristics.

Toxicity Profile: Chronic gastrointestinal (GI) and genitourinary (GU) toxicities were assessed at the 2-year follow-up mark for all patients. Overall, the incidence of treatment-related toxicities was relatively low, with the majority of patients reporting no significant toxicity. Notably, 19.3% of patients experienced RTOG grade 1 GU toxicity, characterized by an increase in frequency of micturition, while one patient (3.2%) developed RTOG grade 2 GU toxicity. Conversely, only one patient (3.2%) experienced RTOG grade 1 GI toxicity in the form of diarrhea, highlighting the favorable toxicity profile associated with the treatment regimen

.

Figure 2-5: Median Serum PSA level at 3 months,6 months, 1year and 2 years was 0.5ng/ml, 0.14ng/ml, 0.12ng/ml, 0.023ng/ml respectively
Sexual dysfunction was reported in 29% of patients, with the median age of affected individuals being 76 years. Interestingly, a subset of patients (9.7%) did not provide feedback on sexual function, underscoring the multifactorial nature of sexual health considerations in this patient population.

Disease Outcomes: At the median follow-up duration of 24.4 months, disease outcomes were evaluated to assess treatment efficacy and disease control. Locoregional recurrence was observed in one patient (3.2%), manifesting as lymph-nodal recurrence. Additionally, distant metastasis, primarily in the form of bone metastases, was identified in three patients (9.7%). Importantly, two patients succumbed to their disease during the follow-up period, with one case attributed to causes unrelated to prostate cancer

.



Figure 6: Comparison of the Dose Schedule.

The findings of this study provide valuable insights into the efficacy and safety of IMRT with SBRT boost in the treatment of high-risk prostatic adenocarcinoma. The favorable toxicity profile observed in the majority of patients underscores the feasibility and tolerability of the treatment regimen, with low rates of treatment-related adverse events. The incidence of locoregional recurrence and distant metastasis, albeit low, highlights the ongoing challenges in achieving durable disease control in this patient population.
The observed outcomes lend support to the hypothesis that the incorporation of SBRT boost within the framework of IMRT facilitates safe dose escalation and enhances treatment efficacy. The relatively low incidence of treatment-related toxicities corroborates the hypothesis that hypofractionation strategies, such as SBRT, offer radiobiological advantages while minimizing the risk of normal tissue toxicity. Additionally, the identification of locoregional recurrence and distant metastasis validates the hypothesis that despite advances in treatment modalities, disease control remains a formidable challenge in high-risk prostatic adenocarcinoma

.



Figure 7: Comparison of the Dosimetry.

Conclusion:
In conclusion, the findings of this retrospective study underscore the feasibility and efficacy of intensity-modulated radiation therapy (IMRT) with stereotactic body radiation therapy (SBRT) boost in the management of high-risk prostatic adenocarcinoma. The observed low incidence of treatment-related toxicities, coupled with favorable disease control outcomes, highlights the potential of this treatment approach to achieve durable disease control while preserving patient quality of life. Despite the challenges posed by this aggressive disease subtype, the integration of advanced radiation techniques offers a promising avenue for optimizing therapeutic outcomes and improving patient prognosis. Moving forward, continued research efforts are warranted to further refine treatment protocols and maximize the therapeutic benefits of IMRT with SBRT boost in this patient population.
Limitations of the Study:
While this study provides valuable insights into the treatment of high-risk prostatic adenocarcinoma, several limitations must be acknowledged. The retrospective nature of the study introduces inherent biases and limitations associated with retrospective analyses, including potential selection bias and incomplete data capture. Additionally, the relatively small sample size may limit the generalizability of findings and hinder the detection of rare adverse events or disease outcomes. Furthermore, the lack of a comparative control group precludes direct comparisons with alternative treatment modalities, necessitating cautious interpretation of results. Despite these limitations, the findings of this study contribute to our understanding of the optimal treatment strategies for high-risk prostate cancer and provide a foundation for future research endeavors in this area.
Implications of the Study:
The findings of this study have important implications for clinical practice and future research in the field of prostate cancer management. The observed efficacy and safety of IMRT with SBRT boost highlight the potential of this treatment approach to serve as a viable alternative or adjunct to conventional treatment modalities in patients with high-risk disease. Furthermore, the favorable toxicity profile observed in this study underscores the importance of individualized treatment planning and optimization of radiation delivery techniques to minimize treatment-related adverse events. These findings may inform clinical decision-making and contribute to the development of evidence-based treatment guidelines for high-risk prostatic adenocarcinoma.
Future Recommendations:
Building upon the findings of this study, several avenues for future research and clinical practice emerge. Firstly, larger prospective studies with longer follow-up durations are warranted to validate the efficacy and

safety of IMRT with SBRT boost in diverse patient populations. Additionally, comparative studies comparing different treatment modalities, including IMRT with SBRT boost versus conventional radiation therapy approaches, may provide further insights into the relative efficacy and toxicity profiles of these treatment strategies. Furthermore, investigations into novel treatment combinations, such as the integration of immunotherapy or targeted agents with radiation therapy, hold promise for improving treatment outcomes in high-risk prostate cancer. Finally, efforts to refine treatment planning techniques and optimize radiation delivery protocols are essential to further enhance the therapeutic benefits of IMRT with SBRT boost in this challenging patient population.

References:

1. *Apetoh L, Golden EB (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25(1): 11-17.*
2. *Bekelman JE, Mitra N, Efstathiou J, Kaijun Liao, Robert Sunderland, et al. (2011) Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 81(4): e325-e334.*
3. *Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424.*
4. *Dearnaley DP, Gordana Jovic, Isabel Syndikus, Vincent Khoo, Richard A Cowan et al. (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15(4): 464-473.*
5. *Fowler J, Chappell R, Ritter M (2001) Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021-1031.*
6. *Fuller DB, Naitoh J, Lee C, Hardy S, Jin H (2008) Virtual HDRSM Cyber Knife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70(5): 1588-1597.*
7. *Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25(1): 11-17.*
8. *Hall EJ, Brenner DJ (1993) The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. International Journal of Radiation Oncology Biology Physics 25(2): 381-385.*
9. *Hoskin PJ, Rojas AM, Bownes PJ, Peter J Ostler, Linda Bryant (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localized prostate cancer. Radiother Oncol 103(2): 217-222.*
10. *Katz AJ, Kang J (2014) Stereotactic body radiotherapy as treatment for organ confined low-and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol 4:240.*
11. *Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, et al. (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2): 275-285.*
12. *Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Peter J Hoskina, Ana M. Rojasa,low asterisk,' Peter J Bownesb, Gerry J Lowea, Peter J Ostlera, Linda Bryanta*
13. *Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85(1): 89-94.*
14. *Weg ES, Pei X, Kollmeier MA, McBride SM, Zelefsky MJ (2019) Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data. Adv Radiat Oncol 4(3): 492-499.*
15. *Wiegner EA, King CR (2010) Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 78: 442-448.*
16. *Zelefsky MJ, Chan H, Hunt M (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176(4 Pt 1): 1415-1419.*
17. *Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB (2013) Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev 39(7): 728-736.*
18. *Fuller DB, Naitoh J, Lee C, Hardy S, Jin H (2008) Virtual HDRSM Cyber Knife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70(5): 1588-1597.*
19. *Peach MS, Showalter TN, Ohri N (2015) Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.*
20. *Fransson P, Olofsson S, Widmark A, Thellenberg Karlsson C (Year) Patient-reported gastrointestinal and genitourinary toxicity after prostate cancer treatment: A comparison between radiotherapy including pelvic nodes and prostate-only radiotherapy. Journal of clinical Oncology*